OYINKAN PENNY: Open Payments
NPI 1417231796 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$11,951 in 70 payments from 17 companies in 2025. Trend: 2023 $10,665 · 2024 $6,848 · 2025 $11,951
Speaker / faculty: $3,780Food & beverage: $3,245Consulting: $3,180Travel & lodging: $1,746
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 10 | $7,644 |
| Novo Nordisk Inc | 2 | $949 |
| ABBVIE INC. | 16 | $827 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $790 |
| Ardelyx, Inc. | 7 | $376 |
| Janssen Biotech, Inc. | 6 | $319 |
| Madrigal Pharmaceuticals | 4 | $210 |
| Mirum Pharmaceuticals, Inc. | 1 | $124 |
| Lilly USA, LLC | 2 | $123 |
| Axsome Therapeutics, Inc. | 1 | $120 |
Products named: VELSIPITY, XIFAXAN, TREMFYA, IBSRELA, MAVYRET, REZDIFFRA, CREON, SKYRIZI.
Industry payments across MO — which companies pay providers there.
